Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BeiGene, Ltd.
  6. Summary
    BGNE   US07725L1026

BEIGENE, LTD.

(BGNE)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/19/2021 07/20/2021 07/21/2021 07/22/2021 07/23/2021 Date
320.59(c) 317.39(c) 306.62(c) 321.73(c) 316.93(c) Last
101 495 302 744 274 481 232 810 304 871 Volume
-1.65% -1.00% -3.39% +4.93% -1.49% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 1 075 M - -
Net income 2021 -1 066 M - -
Net cash position 2021 3 322 M - -
P/E ratio 2021 -30,5x
Yield 2021 -
Sales 2022 1 406 M - -
Net income 2022 -1 032 M - -
Net cash position 2022 2 559 M - -
P/E ratio 2022 -31,0x
Yield 2022 -
Capitalization 29 384 M 29 384 M -
EV / Sales 2021 24,2x
EV / Sales 2022 19,1x
Nbr of Employees 5 400
Free-Float 68,6%
More Financials
Company
BeiGene, Ltd. is principally engaged in biopharmaceutical business. The Company is mainly engaged in the research and development, production and sales of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company's main products include Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317) and Pamiparib (BGB-290). 
More about the company
Ratings of BeiGene, Ltd.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B+
More Ratings
All news about BEIGENE, LTD.
07/21BEIGENE : Regulation FD Disclosure (Form 8-K)
PU
07/21BEIGENE, LTD. : Regulation FD Disclosure, Financial Statements and Exhibits (for..
AQ
07/21PRESS RELEASE : Novartis delivered strong Q2 -2-
DJ
07/12AMGEN : BeiGene Announces the Approval in China of KYPROLIS (Carfilzomib) for In..
AQ
07/09BEIGENE, LTD. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
07/09BEIGENE : Secures Conditional Approval in China for Kyprolis as Treatment for Mu..
MT
07/09BEIGENE : BeiGen Obtains Conditional Approval in China for Multiple Myeloma Trea..
MT
07/09BEIGENE : Announces the Approval in China of KYPROLIS® (Carfilzomib) for Injecti..
BU
07/09BeiGene, Ltd. Announces the Approval in China of KYPROLIS® (Carfilzomib) for ..
CI
07/08BEIGENE : Supplemental Biologics License Application for Tislelizumab Accepted i..
MT
07/08Beigene, Ltd. Announces Acceptance of Supplemental Biologics License Applicat..
CI
07/07BEIGENE : Announces Acceptance of a Supplemental Biologics License Application i..
BU
07/07PURETECH HEALTH : Enters Clinical Trial, Supply Deal With BeiGene Affiliate to T..
MT
07/01BEIGENE, LTD. : Change in Directors or Principal Officers, Financial Statements ..
AQ
07/01BeiGene, Ltd. Announces CFO Changes
CI
More news
News in other languages on BEIGENE, LTD.
07/21GlobeNewswire/Novartis hat im zweiten Quartal -2-
06/21EQS-ADHOC : HBM Portfoliounternehmen Ambrx Biopharma nimmt bei Börsengang an der..
06/04Novartis legt Daten zu Tislelizumab bei Speiseröhrenkrebs vor
04/27GlobeNewswire/Wichtige Wachstumstreiber und -3-
04/27GlobeNewswire/Wichtige Wachstumstreiber und -2-
More news
Analyst Recommendations on BEIGENE, LTD.
More recommendations
Chart BEIGENE, LTD.
Duration : Period :
BeiGene, Ltd. Technical Analysis Chart | BGNE | US07725L1026 | MarketScreener
Technical analysis trends BEIGENE, LTD.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Last Close Price 316,93 $
Average target price 384,73 $
Spread / Average Target 21,4%
EPS Revisions
Managers and Directors
John V. Oyler Chairman & Chief Executive Officer
Xiao Bin Wu President & Chief Operating Officer
Howard Liang Chief Financial & Strategy Officer
Jane E. Huang Chief Medical Officer-Hematology
Yong Ben Chief Medical Officer-Immuno & Oncology Department
Sector and Competitors
1st jan.Capi. (M$)
BEIGENE, LTD.22.66%33 627
GILEAD SCIENCES, INC.18.47%85 134
WUXI APPTEC CO., LTD.37.17%71 226
REGENERON PHARMACEUTICALS21.37%57 013
BIONTECH SE245.88%55 555
VERTEX PHARMACEUTICALS-15.16%50 308